LOTCOL Study: Local Treatment of Colo-rectal Liver Met

A Randomized Study With Palliative Chemotherapy With or Without Local Treatment of Liver Metastases in Patients With Colo-rectal Cancer

Status

Terminated

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01867918

Acronym

LOTCOL

Enrollment

Registered

2013-06-04

Start date

2013-05-31

Completion date

2016-12-31

Last updated

2017-01-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metastatic Colo-rectal Cancer

Brief summary

In this study the investigators will include colo-rectal cancer (CRC) patients starting last line of standard palliative chemotherapy. Eligible patients include patients with KRAS mutation starting line or KRAS wild type starting line treatment. Standard treatment today for these patients is chemotherapy only and median overall survival (OS) is about 10 months. The hypothesis is that local treatment in addition to systemic treatment will increase time to progression, progression free survival and overall survival compared to patients who receive systemic chemotherapy only. The investigators experience with local treatment of liver metastases in CRC patients is that side-effects of treatment in general are minor, although gastric bleeding have been observed after stereotactic body radiation therapy.

Interventions

PROCEDURERadiofrequency ablation, microwave, radiation therapy

Radiofrequency ablation Microwave ablation Radiation therapy

DRUGStandard Chemotherapy

Study design

Allocation

RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Histologically verified adenocarcinoma of colon or rectum * Ambulatory with an ECOG performance status 0-2 * At least 18 years of age * Non-resectable liver metastases * Progressive disease on or within 4 months after 1.line chemotherapy for KRAS mutant or after 2.line chemotherapy in KRAS wild type patients * 1-4 liver metastases with largest diameter of up to 6 cm on CT-scan * Up to 20 lesions in liver with no more than 4 lesions larger than 4 cm * The patients will start 2./3. line chemotherapy (KRAS mutant/KRAS wt) * Laboratory values as the following: * ANC ³ 1.5 x 109/L * Platelets ³ 100 x 109/L * Hb ³ 9g/dL * Creatinine £ 2x upper limit of normal * Bilirubin \< 2.0x the upper limit of normal * ASAT and ALAT £ 5x the upper limit of normal * Albumin levels \> 30 g/L * INR\<1.3 * Signed informed consent and expected cooperation of the patients for the treatment and follow up must be obtained and documented according to ICH GCP, and national/local regulations

Exclusion criteria

* Previous treatment with 2. or 3. line chemotherapy (KRAS mutant/KRAS wt) * History of prior metastatic disease the last 3 years * History of CNS or bone metastases * Significant cardiac or other medical illness that would limit activity or survival, such as severe congestive heart failure, unstable angina, or serious cardiac arrhythmia * Largest liver mets \>6 cm, more than 4 liver lesions \>4 cm * Pulmonary mets\>3 cm * Lymph node mets \>2.5 cm * Chemotherapy/radiation therapy or major surgery within the last 4 weeks before start of treatment * Any reason why, in the opinion of the investigator, the patient should not participate.

Design outcomes

Primary

Measure	Time frame
Overall survival from time of randomization	6 months

Countries

Norway

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026